Hai Tian
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Hai Tian has a total of 188 co-authors. Here are the top co-authors by number of shared publications:
Wei Chen
Department of Cardiovascular Surgery, The Second Affiliated Hospital of Harbin Medical University, Harbin, China
17 shared publicationsLu Sun
Department of Cardiovascular Surgery, Peking University Shenzhen Hospital, Shenzhen, Guangdong Province, China
15 shared publications- Ren-Ke Li
Toronto General Hospital Research Institute, Division of Cardiovascular Surgery, University Health Network, Toronto, Canada; Division of Cardiac Surgery, Department of Surgery, University of Toronto, Toronto, Canada
13 shared publications Chang Liu
Second Affiliated Hospital of Harbin Medical University, 246 Xuefu Road,Nangang District, Harbin, Heilongjiang, 150001, CHINA
10 shared publicationsWei Liu
Key Laboratory of Myocardial Ischemia Harbin Medical University Ministry of Education Harbin, Heilongjiang China
8 shared publicationsKegong Chen
Second Affiliated Hospital of Harbin Medical University, 246 Xuefu Road,Nangang District, Harbin, Heilongjiang, 150001, CHINA
6 shared publications
Latest Publications
- 3 December 2025
- Published by IOP Publishing in Biofabrication
- Vol. 18 (1) , 015010
3D bioprinted epicardial patch of GelMA containing VEGF-loaded chitosan nanoparticles and human bone marrow mesenchymal stem cells for the treatment of myocardial infarction
The transplantation of human bone marrow mesenchymal stem cells (hMSCs) exhibits promising therapeutic effects in the treatment of myocardial infarction (MI), however, its clinical application is limited due to the low survival rate of the transplanted cells. Three-dimensional (3D) bioprinted tissue engineering patches have demonstrated efficacy as a delivery approach to enhance the viability and engraftment of stem cells. In this study, we have developed a novel hMSCs tissue-engineered patch equipped with a nano-slow-release system using 3D bioprinting technology. The patch is based on a matrix material consisting of methacrylated gelatin (GelMA) and chitosan nanoparticles loaded with vascular endothelial growth factor (VEGF), which possesses pro-angiogenic effects. The resulting patch demonstrated excellent compatibility with hMSCs and enabled stable, sustained VEGF release. In vivo results showed that the patch significantly reduced cardiomyocyte apoptosis three days after MI, and improved cardiac function and myocardial fibrosis at 28 d post-surgery. These effects were closely associated with the patch’s potent angiogenic properties and favorable stem cell survival. In conclusion, this study successfully developed a 3D-printed tissue engineering patch with strong potential for clinical application, offering a promising new approach for the treatment of MI.
- 3 December 2025
- Published by IOP Publishing in Biofabrication
- Vol. 18 (1) , 015010
3D bioprinted epicardial patch of GelMA containing VEGF-loaded chitosan nanoparticles and human bone marrow mesenchymal stem cells for the treatment of myocardial infarction
The transplantation of human bone marrow mesenchymal stem cells (hMSCs) exhibits promising therapeutic effects in the treatment of myocardial infarction (MI), however, its clinical application is limited due to the low survival rate of the transplanted cells. Three-dimensional (3D) bioprinted tissue engineering patches have demonstrated efficacy as a delivery approach to enhance the viability and engraftment of stem cells. In this study, we have developed a novel hMSCs tissue-engineered patch equipped with a nano-slow-release system using 3D bioprinting technology. The patch is based on a matrix material consisting of methacrylated gelatin (GelMA) and chitosan nanoparticles loaded with vascular endothelial growth factor (VEGF), which possesses pro-angiogenic effects. The resulting patch demonstrated excellent compatibility with hMSCs and enabled stable, sustained VEGF release. In vivo results showed that the patch significantly reduced cardiomyocyte apoptosis three days after MI, and improved cardiac function and myocardial fibrosis at 28 d post-surgery. These effects were closely associated with the patch’s potent angiogenic properties and favorable stem cell survival. In conclusion, this study successfully developed a 3D-printed tissue engineering patch with strong potential for clinical application, offering a promising new approach for the treatment of MI.
- Open Access
- 22 August 2025
- Published by Elsevier in Materials Today Bio
- Vol. 34, 102234
Cationic microbubble loading hSIRT3 and hTIMP3 optimize cardiac-targeted delivery and myocardial protection in the porcine MI/R model
- 22 August 2025
- Published by Elsevier in Materials Today Bio
- Vol. 34, 102234
Open AccessCationic microbubble loading hSIRT3 and hTIMP3 optimize cardiac-targeted delivery and myocardial protection in the porcine MI/R model
- 23 May 2025
- Published by Elsevier in Free Radical Biology and Medicine
- Vol. 237, 210-227
Cationic microbubbles loading shFOXO4/SDF1 rejuvenate the aged heart and alleviate myocardial ischemia-reperfusion injury in the elderly
- 23 May 2025
- Published by Elsevier in Free Radical Biology and Medicine
- Vol. 237, 210-227
Cationic microbubbles loading shFOXO4/SDF1 rejuvenate the aged heart and alleviate myocardial ischemia-reperfusion injury in the elderly
- 24 January 2025
- Published by Elsevier in Cellular Signalling
- Vol. 127, 111618
Dichloroacetate: A metabolic game-changer in alleviating macrophage inflammation and enhancing recovery after myocardial infarction
- 24 January 2025
- Published by Elsevier in Cellular Signalling
- Vol. 127, 111618
Dichloroacetate: A metabolic game-changer in alleviating macrophage inflammation and enhancing recovery after myocardial infarction
- 30 December 2024
- Published by Springer Nature in Cytotechnology
- Vol. 77 (1) , 29
N6-methyladenosine (m6A) RNA methylation of LncRNA LINC01214 accelerates the progression of non-small cell lung cancer (NSCLC) by targeting miR-195-5p/ROCK1 axis
Long non-coding RNA LINC01214 is reported to be up-regulated in non-small cell lung cancer (NSCLC), however, its function in NSCLC has not been elucidated yet. In our study, we verified that LINC01214 was aberrantly higher in the tumor tissues and cell lines than that in the normal controls, and was relevant to the severity and prognosis of NSCLC through using real-time quantitative PCR. Then, 3-(4,5)-dimethylthiahiazo (-z-y1)-3,5-di-phenytetrazoliumromide assay and flow cytometry illustrated that knocking down LINC01214 restrained cell proliferation and promoted apoptosis in A549 and H1299 cells. Additionally, western blot results confirmed that LINC01214 silence reduced the protein expression of CDK2, CDK6, CyclinD1 and Bcl2, but increased the protein expression of Bax and Caspase-3. Of note, compared to normal cells, NSCLC cells had higher enrichment level of N6-methyladenosine (m6A) modification of LINC01214, while reducing m6A modification of LINC01214 weakened the stability of LINC01214 and diminished its level in A549 and H1299 through down-regulating methyltransferase METTL3 or overexpressing demethylase ALKBH5. Subsequently, molecular experiments proved that LINC01214 acted as a sponge for miR-195-5p to elevate ROCK1 expression in NSCLC. Furthermore, data from functional recovery experiments showed that elevating miR-195-5p also exerted tumor-suppressive effects in NSCLC; meanwhile, the effects were reversed by overexpressing ROCK1 or inhibiting miR-195-5p. In short, m6A modification-mediated up-regulation of LINC01214 advances cell proliferation and tumorigenesis to promote NSCLC progression through inhibiting miR-195-5p to up-regulate ROCK1.
- 30 December 2024
- Published by Springer Nature in Cytotechnology
- Vol. 77 (1) , 29
N6-methyladenosine (m6A) RNA methylation of LncRNA LINC01214 accelerates the progression of non-small cell lung cancer (NSCLC) by targeting miR-195-5p/ROCK1 axis
Long non-coding RNA LINC01214 is reported to be up-regulated in non-small cell lung cancer (NSCLC), however, its function in NSCLC has not been elucidated yet. In our study, we verified that LINC01214 was aberrantly higher in the tumor tissues and cell lines than that in the normal controls, and was relevant to the severity and prognosis of NSCLC through using real-time quantitative PCR. Then, 3-(4,5)-dimethylthiahiazo (-z-y1)-3,5-di-phenytetrazoliumromide assay and flow cytometry illustrated that knocking down LINC01214 restrained cell proliferation and promoted apoptosis in A549 and H1299 cells. Additionally, western blot results confirmed that LINC01214 silence reduced the protein expression of CDK2, CDK6, CyclinD1 and Bcl2, but increased the protein expression of Bax and Caspase-3. Of note, compared to normal cells, NSCLC cells had higher enrichment level of N6-methyladenosine (m6A) modification of LINC01214, while reducing m6A modification of LINC01214 weakened the stability of LINC01214 and diminished its level in A549 and H1299 through down-regulating methyltransferase METTL3 or overexpressing demethylase ALKBH5. Subsequently, molecular experiments proved that LINC01214 acted as a sponge for miR-195-5p to elevate ROCK1 expression in NSCLC. Furthermore, data from functional recovery experiments showed that elevating miR-195-5p also exerted tumor-suppressive effects in NSCLC; meanwhile, the effects were reversed by overexpressing ROCK1 or inhibiting miR-195-5p. In short, m6A modification-mediated up-regulation of LINC01214 advances cell proliferation and tumorigenesis to promote NSCLC progression through inhibiting miR-195-5p to up-regulate ROCK1.
- Open Access
- 10 December 2024
- Published by Springer Nature in Cardiovascular Toxicology
- Vol. 25 (1) , 74-84
Ultrasound-Targeted β-Catenin Gene Therapy Improves the Cardiac Function in Mice After Myocardial Infarction
Gene therapy has received great attention as a therapeutic approach to improve cardiac function post-myocardial infarction (MI), but its limitation lies in the lack of targeting. This study explored the use of ultrasound-targeted microbubble destruction (UTMD) technique to deliver β-catenin gene to the myocardium, aiming to evaluate its efficacy in preventing cardiac dysfunction post-MI. A cationic microbubble solution containing β-catenin gene pcDNA3.1 plasmid was injected through the tail vein at a rate of 0.6 mL/h, and ultrasound beams were delivered to the heart using GE Vivid 7 Medical Ultrasound System M3s Transducer. Bioluminescence imaging was used to analyze the efficiency of UTMD gene transfection into the myocardium. β-catenin levels were detected by real-time polymerase chain reaction and western blot. Additionally, MI was induced in mice by surgical ligation of the left coronary artery, and cardiac function was evaluated using echocardiography at 14 and 28 days post-surgery. Masson’s trichrome staining was employed to determine infarct size. Blood vessel density was also measured. TUNEL assay was used to measure cardiomyocyte apoptosis. Furthermore, mouse cardiac stem cells were isolated using flow cytometry, and Giemsa stain was applied to evaluate the colony adhesion. UTMD delivered the gene to the heart with high efficiency and specificity in vivo. The β-catenin expression was significantly increased in the myocardium (P < 0.01). After MI, the β-catenin group exhibited a notable improvement in the gene therapy-induced neovascularization in the border zone (P < 0.01) and the number and function of cardiac stem cells (P < 0.01), and a significant decrease in cardiomyocyte apoptosis in the heart tissue (P < 0.01). β-catenin gene pre-treated with UTMD can reduce the impact of myocardial injury and promote cardiac self-repair after MI.
- 10 December 2024
- Published by Springer Nature in Cardiovascular Toxicology
- Vol. 25 (1) , 74-84
Open AccessUltrasound-Targeted β-Catenin Gene Therapy Improves the Cardiac Function in Mice After Myocardial Infarction
Gene therapy has received great attention as a therapeutic approach to improve cardiac function post-myocardial infarction (MI), but its limitation lies in the lack of targeting. This study explored the use of ultrasound-targeted microbubble destruction (UTMD) technique to deliver β-catenin gene to the myocardium, aiming to evaluate its efficacy in preventing cardiac dysfunction post-MI. A cationic microbubble solution containing β-catenin gene pcDNA3.1 plasmid was injected through the tail vein at a rate of 0.6 mL/h, and ultrasound beams were delivered to the heart using GE Vivid 7 Medical Ultrasound System M3s Transducer. Bioluminescence imaging was used to analyze the efficiency of UTMD gene transfection into the myocardium. β-catenin levels were detected by real-time polymerase chain reaction and western blot. Additionally, MI was induced in mice by surgical ligation of the left coronary artery, and cardiac function was evaluated using echocardiography at 14 and 28 days post-surgery. Masson’s trichrome staining was employed to determine infarct size. Blood vessel density was also measured. TUNEL assay was used to measure cardiomyocyte apoptosis. Furthermore, mouse cardiac stem cells were isolated using flow cytometry, and Giemsa stain was applied to evaluate the colony adhesion. UTMD delivered the gene to the heart with high efficiency and specificity in vivo. The β-catenin expression was significantly increased in the myocardium (P < 0.01). After MI, the β-catenin group exhibited a notable improvement in the gene therapy-induced neovascularization in the border zone (P < 0.01) and the number and function of cardiac stem cells (P < 0.01), and a significant decrease in cardiomyocyte apoptosis in the heart tissue (P < 0.01). β-catenin gene pre-treated with UTMD can reduce the impact of myocardial injury and promote cardiac self-repair after MI.
- Open Access
- 23 November 2023
- Published by Wiley in Exploration
- Vol. 4 (3) , 20230067
Ion cocktail therapy for myocardial infarction by synergistic regulation of both structural and electrical remodeling
Myocardial infarction (MI) is a leading cause of death worldwide. Few drugs hold the ability to depress cardiac electrical and structural remodeling simultaneously after MI, which is crucial for the treatment of MI. The aim of this study is to investigate an effective therapy to improve both electrical and structural remodeling of the heart caused by MI. Here, an “ion cocktail therapy” is proposed to simultaneously reverse cardiac structural and electrical remodeling post‐MI in rats and minipigs by applying a unique combination of silicate, strontium (Sr) and copper (Cu) ions due to their specific regulatory effects on the behavior of the key cells involved in MI including angiogenesis of endothelial cells, M2 polarization of macrophages and apoptosis of cardiomyocyte. The results demonstrate that ion cocktail treatment attenuates structural remodeling post‐MI by ameliorating infarct size, promoting angiogenesis in both peri‐infarct and infarct areas. Meantime, to some extent, ion cocktail treatment reverses the deteriorative electrical remodeling by reducing the incidence rate of early/delayed afterdepolarizations and minimizing the heterogeneity of cardiac electrophysiology. This ion cocktail therapy reveals a new strategy to effectively treat MI with great clinical translation potential due to the high effectiveness and safety of the ion cocktail combination.
- 23 November 2023
- Published by Wiley in Exploration
- Vol. 4 (3) , 20230067
Open AccessIon cocktail therapy for myocardial infarction by synergistic regulation of both structural and electrical remodeling
Myocardial infarction (MI) is a leading cause of death worldwide. Few drugs hold the ability to depress cardiac electrical and structural remodeling simultaneously after MI, which is crucial for the treatment of MI. The aim of this study is to investigate an effective therapy to improve both electrical and structural remodeling of the heart caused by MI. Here, an “ion cocktail therapy” is proposed to simultaneously reverse cardiac structural and electrical remodeling post‐MI in rats and minipigs by applying a unique combination of silicate, strontium (Sr) and copper (Cu) ions due to their specific regulatory effects on the behavior of the key cells involved in MI including angiogenesis of endothelial cells, M2 polarization of macrophages and apoptosis of cardiomyocyte. The results demonstrate that ion cocktail treatment attenuates structural remodeling post‐MI by ameliorating infarct size, promoting angiogenesis in both peri‐infarct and infarct areas. Meantime, to some extent, ion cocktail treatment reverses the deteriorative electrical remodeling by reducing the incidence rate of early/delayed afterdepolarizations and minimizing the heterogeneity of cardiac electrophysiology. This ion cocktail therapy reveals a new strategy to effectively treat MI with great clinical translation potential due to the high effectiveness and safety of the ion cocktail combination.
- 20 June 2023
- Published by China Scientific Research Publishing Pte. Ltd. in JOURNAL OF BIOLOGICAL REGULATORS AND HOMEOSTATIC AGENTS
- Vol. 37 (6) , 3221-3239
Identification of Hub Genes and Molecular Mechanisms in Acute Stanford Type A Aortic Dissection
Background: Acute Stanford type A aortic dissection (ATAAD) is a potentially fatal outcome of cardiac surgery with a high mortality rate and an unclear pathogenesis. This study aimed to investigate the prospective diagnostic biomarkers and molecular pathways in ATAAD. Methods: We identified autophagy-related differentially expressed genes (DEGs) between control ATAAD groups using three Gene Expression Omnibus (GEO) datasets (GSE153434, GSE98770, and GSE52093). The potential pathways and biomarkers were then determined through protein-protein interaction (PPI) network and enrichment analysis. The autophagy-related hub genes and their corresponding diagnostic values were determined using receiver operating characteristic analysis and the significant immune-associated pathways were identified using Gene-Set Variation Analysis (GSVA) enrichment. Results: A total of 90 genes were screened as autophagy-related DEGs and 10 hub genes were ultimately identified using a PPI network in patients with ATAAD. Autophagy-related DEGs were enriched in pathways related to autophagy, protein binding, regulation of autophagy, and the relaxin signaling pathway according to Gene Ontology and Kyoto Encyclopedia of Genes and Genomes analyses. Gene-set enrichment analysis suggested that the regulation of autophagosome assembly, focal adhesion, and calcium-signaling pathways are enriched mainly in ATAAD development. In addition, GSVA showed that DEGs in ATAAD are primarily involved in the metabolic pathways of myocardial diseases and autophagy. Finally, it was found that the immune infiltration between the control and ATAAD groups was significantly different. Conclusions: Through the comprehensive analysis of GEO data, our study provides insights into autophagy-related biomarkers and therapeutic targets to diagnose and treat patients who are susceptible to ATAAD.
- 20 June 2023
- Published by China Scientific Research Publishing Pte. Ltd. in JOURNAL OF BIOLOGICAL REGULATORS AND HOMEOSTATIC AGENTS
- Vol. 37 (6) , 3221-3239
Identification of Hub Genes and Molecular Mechanisms in Acute Stanford Type A Aortic Dissection
Background: Acute Stanford type A aortic dissection (ATAAD) is a potentially fatal outcome of cardiac surgery with a high mortality rate and an unclear pathogenesis. This study aimed to investigate the prospective diagnostic biomarkers and molecular pathways in ATAAD. Methods: We identified autophagy-related differentially expressed genes (DEGs) between control ATAAD groups using three Gene Expression Omnibus (GEO) datasets (GSE153434, GSE98770, and GSE52093). The potential pathways and biomarkers were then determined through protein-protein interaction (PPI) network and enrichment analysis. The autophagy-related hub genes and their corresponding diagnostic values were determined using receiver operating characteristic analysis and the significant immune-associated pathways were identified using Gene-Set Variation Analysis (GSVA) enrichment. Results: A total of 90 genes were screened as autophagy-related DEGs and 10 hub genes were ultimately identified using a PPI network in patients with ATAAD. Autophagy-related DEGs were enriched in pathways related to autophagy, protein binding, regulation of autophagy, and the relaxin signaling pathway according to Gene Ontology and Kyoto Encyclopedia of Genes and Genomes analyses. Gene-set enrichment analysis suggested that the regulation of autophagosome assembly, focal adhesion, and calcium-signaling pathways are enriched mainly in ATAAD development. In addition, GSVA showed that DEGs in ATAAD are primarily involved in the metabolic pathways of myocardial diseases and autophagy. Finally, it was found that the immune infiltration between the control and ATAAD groups was significantly different. Conclusions: Through the comprehensive analysis of GEO data, our study provides insights into autophagy-related biomarkers and therapeutic targets to diagnose and treat patients who are susceptible to ATAAD.